Literature DB >> 21442269

Treatment of pediatric refractory status epilepticus with topiramate.

Başak Nur Akyildiz1, Sefer Kumandaş.   

Abstract

OBJECTIVE: We evaluated a topiramate (TPM) regimen for treating refractory status epilepticus in the largest pediatric series, reported to date.
METHODS: Fourteen patients received TPM via the nasogastric route. Initially, all patients received TPM as a 5 mg/kg loading dose followed by 5 mg/kg/day in two doses as maintenance. Thereafter, patients were divided into three groups based on the response to TPM therapy and seizure cessation time (full responder, partial responder, and nonresponder). Four patients received only thiopental, two received thiopental, and high-dose midazolam, one received thiopental, high-dose midazolam, and propofol, two received only propofol, one received propofol, and high-dose midazolam and four patients were on a high-dose midazolam infusion.
RESULTS: The median time to seizure cessation was 5.5 h (range 2-48 h). Nine patients were full responders, three were partial responders, and two were nonresponders At follow-up, six patients were weaned successfully from thiopental, two patients from high-dose midazolam and three patients from propofol. Three patients developed mild metabolic acidosis during TPM theraphy.
CONCLUSIONS: Most of the patients responded to this treatment which was well tolerated. So we recommended its use for terminating refractory status epilepticus in children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21442269     DOI: 10.1007/s00381-011-1432-y

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  21 in total

1.  Refractory status epilepticus in 2001.

Authors:  Thomas P Bleck
Journal:  Arch Neurol       Date:  2002-02

Review 2.  The use of topiramate in refractory status epilepticus.

Authors:  A R Towne; L K Garnett; E J Waterhouse; L D Morton; R J DeLorenzo
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

3.  Topiramate and metabolic acidosis in pediatric epilepsy.

Authors:  M Takeoka; G L Holmes; E Thiele; B F Bourgeois; S L Helmers; F H Duffy; J J Riviello
Journal:  Epilepsia       Date:  2001-03       Impact factor: 5.864

Review 4.  Treatment of refractory status epilepticus: literature review and a proposed protocol.

Authors:  Nicholas S Abend; Dennis J Dlugos
Journal:  Pediatr Neurol       Date:  2008-06       Impact factor: 3.372

5.  Refractory status epilepticus: frequency, risk factors, and impact on outcome.

Authors:  Stephan A Mayer; Jan Claassen; Johnny Lokin; Felicia Mendelsohn; Lyle J Dennis; Brian-Fred Fitzsimmons
Journal:  Arch Neurol       Date:  2002-02

6.  Pediatric refractory partial status epilepticus responsive to topiramate.

Authors:  Lubov Blumkin; Tally Lerman-Sagie; Tzion Houri; Eli Gilad; Andrea Nissenkorn; Mira Ginsberg; Nathan Watemberg
Journal:  J Child Neurol       Date:  2005-03       Impact factor: 1.987

7.  Outcome of severe refractory status epilepticus in children.

Authors:  M Sahin; C C Menache; G L Holmes; J J Riviello
Journal:  Epilepsia       Date:  2001-11       Impact factor: 5.864

8.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.

Authors:  E Faught; B J Wilder; R E Ramsay; R A Reife; L D Kramer; G W Pledger; R M Karim
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

9.  Levetiracetam in children with refractory status epilepticus.

Authors:  William B Gallentine; Addie S Hunnicutt; Aatif M Husain
Journal:  Epilepsy Behav       Date:  2008-11-28       Impact factor: 2.937

Review 10.  Topiramate: as monotherapy in newly diagnosed epilepsy.

Authors:  John Waugh; Karen L Goa
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more
  13 in total

Review 1.  Newer antiepileptic drugs: evidence based use.

Authors:  Gouri Rao Passi
Journal:  Indian J Pediatr       Date:  2014-06-25       Impact factor: 1.967

Review 2.  Antiseizure medications in critical care: an update.

Authors:  Baxter Allen; Paul M Vespa
Journal:  Curr Opin Crit Care       Date:  2019-04       Impact factor: 3.687

3.  Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study.

Authors:  Annalena Hottinger; Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

4.  Management of pediatric status epilepticus.

Authors:  Nicholas S Abend; Tobias Loddenkemper
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

Review 5.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

6.  Enteral topiramate in a pediatric patient with refractory status epilepticus: a case report and review of the literature.

Authors:  Chasity M Shelton; Elizabeth L Alford; Stephanie Storgion; James Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

7.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Saima Kayani; Deepa Sirsi
Journal:  J Cent Nerv Syst Dis       Date:  2012-03-08

Review 8.  Management of Status Epilepticus in Children.

Authors:  Douglas M Smith; Emily L McGinnis; Diana J Walleigh; Nicholas S Abend
Journal:  J Clin Med       Date:  2016-04-13       Impact factor: 4.241

9.  Intravenous Topiramate: Pharmacokinetics in Dogs with Naturally Occurring Epilepsy.

Authors:  Irene Vuu; Lisa D Coles; Patricia Maglalang; Ilo E Leppik; Greg Worrell; Daniel Crepeau; Usha Mishra; James C Cloyd; Edward E Patterson
Journal:  Front Vet Sci       Date:  2016-12-05

Review 10.  Topiramate in the Treatment of Generalized Convulsive Status Epilepticus in Adults: A Systematic Review with Individual Patient Data Analysis.

Authors:  Francesco Brigo; Nicola Luigi Bragazzi; Stanley C Igwe; Raffaele Nardone; Eugen Trinka
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.